Centro Nacional de Biotecnología (CNB-CSIC)

National Biotechnology Centre (CNB-CSIC)

Information
C/ Darwin nº 3, Campus de Cantoblanco 28049 Madrid

cancer, covid-19, gene editing, rare diseases, immunology, microbiology, nanoscience, AIDS / HIV, transgenics
Contact
Susana de Lucas
Communication and scientific dissemination
divulgacion@cnb.csic.es
91 585 48 42

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Co-director of the Microbiome Analysis Laboratory and Research Professor

Co-director of the coronavirus group at the National Biotechnology Centre (CNB-CSIC)

Research professor at the National Biotechnology Centre (CNB-CSIC) and at the CIBERER-ISCIII

 

CNB-CSIC Scientific Researcher at the CiMUS of the University of Santiago de Compostela, IDIS. Laboratory of Cell Senescence, Cancer and Aging.

Virologist at the National Center for Biotechnology (CNB-CSIC)

Researcher at the National Biotechnology Centre (CNB-CSIC)

Researcher specialized in ecology and evolution of antibiotic resistance.

Virologist at the National Biotechnology Centre (CNB-CSIC)

CSIC Research Professor at the National Center of Biotechnology

Contents related to this centre
baby

A team from the Children's Hospital of Philadelphia and Penn Medicine (United States) has successfully treated a baby diagnosed with a rare genetic disorder using personalised CRISPR gene editing therapy. The baby, known only by the initials KJ, was born with a rare metabolic disease known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. After spending the first months of his life in hospital on a very restrictive diet, KJ received the first dose of his tailored therapy in February 2025, between six and seven months of age. The treatment, which is being used for the first time for this type of disorder, was administered safely, and the baby is now growing well and improving. The case is detailed in a study published by The New England Journal of Medicine (NEJM).

woman

23% of people infected with SARS-CoV-2 between 2021 and 2023 developed long covid and more than half of them had persistent symptoms for two years. These are the main conclusions of a study led by ISGlobal that followed more than 2,700 people in Catalonia. The results are published in the journal BMC Medicine.

mice

Colossal Biosciences has announced the creation of genetically modified mice with characteristics reminiscent of the fur of extinct mammoths, such as fur colour, texture and thickness. The non-peer-reviewed results were shared today in the BioRXiv prepublication repository.

heat

Research has analyzed how extreme heat influences the biological age of elderly populations, specifically in the United States. The study, published in Science Advances, used blood samples from more than 3,600 adults with an average age of 68 collected between 2010 and 2016. The team compared epigenetic aging trends with the number of days of extreme heat in the participants' places of residence. The models showed that more days of heat or long-term heat — over a period of one to six years — increased the biological age of the participants by more than two years.

Aging

An international team has analyzed data from nearly half a million people to analyze the influence of genes or environment on mortality, age-related diseases and aging. Although the relationship may vary according to the type of disease, their conclusions are that the environment -especially socioeconomic conditions, smoking habits and physical exercise- has a much greater influence than genetics in all the aspects studied. Among other data, environment explains 17 % of the variation in mortality risk, while genetics is limited to 2 %. The results are published in the journal Nature Medicine. 

laboratory mouse

A team of researchers has used embryonic stem cell engineering to create a bipaternal mouse - a mouse with two male parents - that lived to adulthood. Their results, published in the journal Cell Stem Cell, show how targeting a particular set of genes involved in reproduction enabled this breakthrough in unisexual reproduction in mammals.

Bacteria

Thirty eight scientists from different specialties, including Craig Venter, a pioneer in the creation of artificial synthetic life, have written an article in the journal Science in which they assess the possibilities of synthesizing mirror organisms, but also warn of the risks they pose. This type of microorganisms, which would present a mirror structure to that currently found in nature, would have potential applications due to their resistance to biological degradation. However, they would also pose a danger because they would not be recognized by our defenses and could spread in ecosystems. Scientists call for more research and a broad debate, and warn that until more is known, this type of organism should not be created. 

 

ADN

Two articles published in Nature describe a new genome editing technique that enables the insertion, inversion, or deletion of long DNA sequences at specific positions in the genome. This is a one-step approach that could offer a simpler method for genome editing in the future. The authors describe a technique to create reprogrammable recombinases—key enzymes in genetic recombination. These enzymes are guided by RNA, which acts as a bridge, directing the recombinase to target sites and facilitating predetermined editing.

mice

Five out of ten potential treatments move from animal studies to human studies; four to randomised controlled clinical trials; and one in 20 moves on to approval by regulatory agencies, an analysis estimates. Concordance between positive results in animals and in clinical studies is 86%, according to the study, published in PLoS Biology, which pools the findings of 122 published studies on 54 different human diseases.  

HIV

The Science group is simultaneously publishing four papers (two in the journal Science, one in Science Immunology and one in Science Translational Medicine) that include advances in a sequential vaccination strategy for an effective HIV vaccine. The methods employed aim to obtain broad-spectrum neutralising antibodies and one of the proposals is already in clinical trials.